BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23887305)

  • 1. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.
    Kuhn E; Ayhan A; Shih IeM; Seidman JD; Kurman RJ
    Mod Pathol; 2014 Feb; 27(2):231-7. PubMed ID: 23887305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
    Cuatrecasas M; Catasus L; Palacios J; Prat J
    Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
    Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
    Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
    Tafe LJ; Muller KE; Ananda G; Mitchell T; Spotlow V; Patterson SE; Tsongalis GJ; Mockus SM
    Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor?
    Wang L; Allison D; Shukla PS
    Am J Clin Pathol; 2020 Jun; 154(1):133-141. PubMed ID: 32322877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
    Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
    Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
    Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
    J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium.
    Kuhn E; Ayhan A; Shih IeM; Seidman JD; Kurman RJ
    Eur J Cancer; 2013 Dec; 49(18):3839-49. PubMed ID: 24012099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borderline Brenner Tumor: A Review of the Literature.
    Zheng R; Heller DS
    Arch Pathol Lab Med; 2019 Oct; 143(10):1278-1280. PubMed ID: 30779594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
    Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
    Pfarr N; Darb-Esfahani S; Leichsenring J; Taube E; Boxberg M; Braicu I; Jesinghaus M; Penzel R; Endris V; Noske A; Weichert W; Schirmacher P; Denkert C; Stenzinger A
    Genes Chromosomes Cancer; 2017 Oct; 56(10):758-766. PubMed ID: 28639280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.
    Kim YM; Lee SW; Chun SM; Kim DY; Kim JH; Kim KR; Kim YT; Nam JH; van Hummelen P; MacConaill LE; Hahn WC; Jang SJ
    PLoS One; 2014; 9(6):e99451. PubMed ID: 24936796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma.
    Khani F; Diolombi ML; Khattar P; Huang W; Fallon JT; Epstein JI; Zhong M
    Am J Surg Pathol; 2016 Sep; 40(9):1291-5. PubMed ID: 27299795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study.
    De Cecio R; Cantile M; Collina F; Marra L; Santonastaso C; Scaffa C; Botti G; Losito NS
    J Ovarian Res; 2014 Oct; 7():101. PubMed ID: 25358264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
    Agell L; Hernández S; Salido M; de Muga S; Juanpere N; Arumí-Uria M; Menendez S; Lorenzo M; Lorente JA; Serrano S; Lloreta J
    Mod Pathol; 2011 Mar; 24(3):443-52. PubMed ID: 21113138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications.
    Logani S; Oliva E; Amin MB; Folpe AL; Cohen C; Young RH
    Am J Surg Pathol; 2003 Nov; 27(11):1434-41. PubMed ID: 14576476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.